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While the initiation of the adaptive and innate immune response is well understood, less is known about 
cellular mechanisms propagating inflammation. The receptor for advanced glycation end products (RAGE), 
a transmembrane receptor of the immunoglobulin superfamily, leads to perpetuated cell activation. Using 
novel animal models with defective or tissue-specific RAGE expression, we show that in these animal models 
RAGE does not play a role in the adaptive immune response. However, deletion of RAGE provides protec-
tion from the lethal effects of septic shock caused by cecal ligation and puncture. Such protection is reversed 
by reconstitution of RAGE in endothelial and hematopoietic cells. These results indicate that the innate 
immune response is controlled by pattern-recognition receptors not only at the initiating steps but also at 
the phase of perpetuation.
Introduction
The adaptive and the innate immune systems are both capable 
of initiating inflammation. The two are interconnected at several 
levels, including the synthesis and action of cytokines, molecules 
regulating cell-cell interactions, and the activation of transcription 
factors (1–9). While the molecular events leading to activation of 
the immune response are well understood, less is known about 
factors that perpetuate inflammation. One mechanism considered 
central in the cross-talk between the innate and adaptive immune 
systems is the redox-dependent activation of the transcription 
factor NF-κB (1, 4, 9–13). Members of the NF-κB family control 
the initiation of inflammation by regulating expression of leuko-
cyte adhesion molecules, cytokines, and other factors (10–13), but 
are also central in terminating inflammation (14–18). This leaves 
unanswered the question of the perpetuation of inflammation of 
the adaptive and innate immune responses.
Recently, studies of the receptor for advanced glycation end 
products (RAGE) (19–23), a member of the immunoglobulin 
superfamily (23) whose gene is located in the vicinity of the MHC 
complex in humans and mice (23, 24), have served to partially 
answer this question. Previous studies suggested that binding of 
ligands to RAGE results in rapid and sustained cellular activation 
and gene transcription (25). Its involvement in inflammation has 
been suggested by many findings. First, RAGE is upregulated in 
all inflammatory lesions studied, including rheumatoid arthri-
tis (26–28), inflammatory kidney disease (29–32), arteriosclerosis 
(33–36), inflammatory bowel disease (37), and others (38–42). 
Second, soluble RAGE (sRAGE), which is a truncated form of the 
receptor spanning the extracellular ligand-binding domain (and 
which therefore competes with cellular RAGE for ligand bind-
ing), reduced inflammatory responses in all models tested so far 
(35–40, 42, 43), such as delayed-type hypersensitivity (DTH), coli-
tis, and periodontitis. Studies using F(ab)2 fragments to block 
ligand binding to RAGE confirmed these results, especially at 
the highest dose tested.
As reported for pattern-recognition receptors (PRRs) of the 
innate immune system, RAGE is a receptor that recognizes a three-
dimensional structure rather than a specific amino acid sequence 
(5, 6, 8, 44). RAGE binds several peptides, including advanced gly-
cated end products, amyloid β-peptide, S100 proteins, and ampho-
terin, also known as high-mobility group protein B1 (HMGB1), 
all of which are characterized by the presence of β-sheet structures 
and fibrils (20, 28, 45). sRAGE functions as a “decoy” by binding 
RAGE ligands and preventing their interaction with cell surface 
RAGE. However, sRAGE also has the capacity to prevent ligands 
from interacting with receptors other than RAGE. In order to be 
certain that a particular response was RAGE dependent, it was nec-
essary to generate and study homozygous RAGE-null (RAGE–/–) 
mice. We have generated such mice devoid of RAGE, as well as mice 
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with tissue-specific expression, in order to study the role of this 
PRR in adaptive and innate immune responses.
The data presented here show that RAGE–/– mice reacted normal-
ly in different models of the adaptive immune response tested but 
were protected in a model of lethal septic shock, the latter depen-
dent on the innate immune response. These data indicate that the 
innate immune response is controlled by PRRs not only at the point 
of initiation but also during the propagation phase.
Results
Generation of mice carrying a RAGE–/– mutation or overexpressing RAGE 
in specific tissues. For the generation of a RAGE–/– mouse line, essen-
tial elements encoding the extracellular domain of RAGE (exons 
2–7) were flanked by two loxP sites in the same orientation so that 
after exposure to Cre recombinase (Cre), the intervening genomic 
sequences were deleted. Mice heterozygous for Cre recombination 
were bred to homozygosity to generate the RAGE–/– mouse line. The 
abrogation of RAGE expression at the mRNA level was analyzed by 
RT-PCR of lung tissue, in which RAGE is constitutively expressed 
at high levels. No RAGE mRNA could be detected in RAGE–/– mice 
with primers for the extracellular RAGE domain (Figure 1A). To 
confirm the abrogation of RAGE expression, we used different prim-
ers covering the entire RAGE molecule and detected no transcripts 
(data not shown). In addition, in tissues with low RAGE expression 
in wild-type (WT) mice (heart, liver, kidney, and brain), no RAGE 
message could be detected in RAGE–/– mice (data not shown). The 
absence of RAGE protein was demonstrated by Western blot and 
immunohistochemistry of lung tissue (Figure 1, B and C).
Hematopoietic and endothelial cells are cell types important in 
inflammatory reactions during an immune response. Therefore, 
mice overexpressing RAGE in hematopoietic and endothelial cells 
were generated. Two distinct regulatory elements of the murine 
Tie2 gene were chosen to drive the RAGE transgene: a 2.1-kb pro-
moter sequence and a 10.5-kb fragment including enhancer frag-
ments (Figure 2A) (46). The presence of the RAGE transgene was 
analyzed by Southern blot of DNA obtained from tail tissue (Fig-
ure 2B). RAGE expression was evaluated in different vascularized 
tissues of heterozygous Tie2RAGE mice (mice with the Tie2 pro-
moter and Tie2 enhancer to drive RAGE expression) by RT-PCR 
(Figure 2C). Strong upregulation of RAGE transcripts was detected 
in kidney, brain, and liver, organs with rather low RAGE expression 
in healthy WT mice, while no upregulation of RAGE mRNA could 
be detected in the lung (Figure 2C). This was most likely due to 
the high constitutive RAGE expression evident in lung epithelia of 
WT mice (47) not affected by Tie2-driven overexpression of RAGE. 
RT-PCR was also performed using primer pairs covering the whole 
Figure 1
Generation and characterization of RAGE–/– mouse line. (A) RT-PCR 
of lung tissue from RAGE–/– and WT mice analyzed for RAGE mRNA 
expression. WT indicates RAGE+/+ littermates. HPRT was used to dem-
onstrate equal loading. (B) Western blot analysis of RAGE–/– and WT 
lung tissue analyzed for the presence of RAGE protein (43 kDa). Tubu-
lin demonstrates equal loading. (C) Immunohistology for RAGE protein 
in WT and RAGE–/– lung tissue. Brown staining indicates RAGE expres-
sion; magnification, ×400.
Figure 2
Generation and characterization of the Tie2RAGE 
mouse line. (A) Tie2RAGE construct. Genomic RAGE 
DNA was cloned between the Tie2 promoter and 
enhancer. Gray boxes indicate RAGE exons; Roman 
numerals indicate RAGE exon numbers. E, EcoRI 
restriction enzyme site. (B) Southern blot analysis of 
DNA obtained from tail biopsies from WT and Tie2RAGE 
mice; EcoRI digestion releases a 2.2-kb DNA fragment 
from the Tie2RAGE transgene. (C) RT-PCR of differ-
ent tissues derived from Tie2RAGE (Tie2) and WT 
mice analyzed for RAGE mRNA expression. WT indi-
cates transgene-negative littermates. HPRT was used 
to demonstrate equal loading. (D) Immunohistology 
for RAGE protein in Tie2RAGE and WT kidney tissue. 
Brown staining indicates RAGE expression; magnifica-
tion, ×400. RAGE expression in kidneys of Tie2RAGE 
mice is evident in the endothelium of large and small 
vessels, while no RAGE protein could be detected in 
kidneys of healthy WT mice.
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receptor to ensure expression of the entire molecule, and RAGE 
overexpression was quantified by real-time PCR (Taq Man). The 
full-length RAGE molecule was expressed in Tie2RAGE mice, and 
quantification demonstrated at least ten times more RAGE tran-
scripts in kidney, spleen, liver, and brain of Tie2RAGE mice than 
in those of WT mice (data not shown). Renal tissue was subjected 
to immunohistology to demonstrate RAGE transgene expression 
in distinct cell types. RAGE expression in Tie2RAGE kidneys was 
restricted to the endothelium of large and small vessels, whereas 
RAGE protein could not be detected in WT tissue (Figure 2D).
RAGE–/– and Tie2RAGE mice were viable and displayed normal 
reproductive fitness. No spontaneous disease development was 
observed in mice up to the age of 6 months; mice were housed 
under specific pathogen–free (SPF) conditions. Mice displayed 
normal macroscopic pathology and histopathology.
Because ligation of RAGE results in sustained activation of 
NF-κB (25), electrophoretic mobility-shift assay (EMSA) was 
performed to define the extent of (carboxymethyl)lysine-medi-
ated (CML-mediated) NF-κB inducibility in the different mouse 
mutants. WT, RAGE–/–, Tie2RAGE, and Tie2RAGE × RAGE–/– mice 
received a single intraperitoneal dose of 1,000 μg CML-modified 
hemoglobin or control hemoglobin. Total blood was collected 
6 days later and was subjected to NF-κB–specific EMSA. Promi-
nent NF-κB–binding activity induced by CML was observed in the 
blood of WT, Tie2RAGE, and Tie2RAGE × RAGE–/– mice and was 
absent from RAGE–/– mice (Figure 3). These data confirm the lack 
of abundant NF-κB activation in RAGE–/– mice exposed to RAGE 
ligands. In contrast, Tie2RAGE mice responded with increased and 
perpetuated NF-κB activation after a single CML challenge and 
thus have intracellular signaling capabilities that mediate RAGE-
dependent NF-κB activation (Figure 3). Furthermore, Tie2-driven 
RAGE overexpression in hematopoietic and endothelial cells was 
sufficient to reconstitute CML-dependent NF-κB inducibility in 
total blood of RAGE-deficient mice (Figure 3).
Normal adaptive immune responses in RAGE mutant mice. No differ-
ence was observed in the development of immunocompetent cells 
in WT and RAGE–/– mice, as assessed by determination of the devel-
opment of T cells in the thymus with flow cytometry as well as by 
comparison of the numbers of B and T cells in the spleen (data not 
shown). The experimental autoimmune encephalomyelitis (EAE) 
model (myelin oligodendrocyte glycoprotein [MOG] model) was 
selected as an autoimmune model to analyze the immune com-
petence of RAGE mutant mice in vivo. This model allows study of 
the functionality of initiation of the adaptive immune response, 
inflammation, migration of immune competent cells, and tissue 
destruction. EAE was induced in RAGE–/–, Tie2RAGE, and WT 
mice. RAGE–/– mice developed typical EAE symptoms, and no sig-
nificant difference was found by comparison of the mean clinical 
disease scores of WT and RAGE–/– mice in various independent 
experiments, of which two are shown in Figure 4A. These results 
demonstrate that the initiation of the adaptive immune response, 
migration of immunocompetent cells, and destruction of myelin 
sheets leading to paralysis of RAGE mutant mice are comparable 
Figure 3
NF-κB inducibility in peripheral blood mononuclear cells of the 
various mouse strains. Six-month-old WT, RAGE–/–, Tie2RAGE, or 
Tie2RAGE × RAGE–/– mice received unmodified control hemoglobin 
(Contr.-Hg) or CML-modified hemoglobin (CML-Hg) (1,000 μg/mouse 
at time point 0, intraperitoneally). Six days later, mice were sacrificed 
and NF-κB–binding activity was determined in total blood. Recombi-
nant NF-κB (Rec. NF-κB) produced in erythrocyte lysates served as 
control for NF-κB binding. To confirm NF-κB binding, binding activity 
at 6 days was competed with a 160-fold molar excess of unlabeled 
consensus NF-κB oligonucleaotides (cons.). Arrowheads indicate 
NF-κB complexes consisting of NF-κB homodimers or NF-κB (p50/
p65) heterodimers, respectively.
Figure 4
RAGE–/– and Tie2RAGE mice develop a normal immune response in 
EAE. Age- and sex-matched mice were sensitized against oligoden-
drocyte glycoprotein (MOG35–55) and were monitored for the onset 
of clinical signs on a daily basis (see Methods). (A) EAE response 
in WT and RAGE–/– mice. WT indicates C57BL/6 × 129/Sv mice. The 
mean clinical score represents a summary of two independent experi-
ments each for WT and for RAGE–/–. WT, filled squares; RAGE–/–, open 
circles. (B) EAE response in WT and Tie2RAGE mice. WT mice used 
were transgene-negative littermates. The mean clinical score repre-
sents a summary of two independent experiments each for WT and for 
Tie2RAGE. WT, filled squares; Tie2RAGE, open triangles. The stan-
dard error of the mean is given (± SEM), and P < 0.05 was considered 
to be statistically significant.
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to those of WT mice. In contrast, the mean clinical EAE scores of 
WT and Tie2RAGE mice were statistically different (P = 0.02; Fig-
ure 4B), indicating that amplification of EAE is promoted in mice 
overexpressing RAGE. Consistent with our results, in the myelin 
basic protein (MBP) model of EAE (a model most closely mimick-
ing an acute initial episode of EAE), RAGE blockade via several 
approaches (see Discussion) reduced the intensity of the inflam-
matory cell infiltrate and symptomatology, although not the gen-
eration of a humoral or cell-mediated response to MBP (48).
Likewise, in the MOG model of EAE, RAGE-deficient mice did 
not show any abnormalities in various other adaptive immune 
responses in vitro and in vivo, including generation of alloreactive 
cytotoxic T cells in vitro, skin allograft rejection, graft-versus-host 
disease (GvHD), and antibody production against Pasteurella pneu-
motropica Jawetz NTC8141 (data not shown).
Reduction in DTH responses by sRAGE in RAGE–/– mice. Using a DTH 
model, we previously demonstrated a significant reduction of the 
inflammatory response in mice after application of sRAGE (37). 
One interpretation of these results would assign RAGE a central 
role as a mediator of inflammation in DTH. To test this hypoth-
esis, we induced DTH in RAGE–/– mice. However, RAGE–/– mice 
developed the same inflammatory response as WT controls. The 
mean inflammation score, as assessed in two independent experi-
ments, is shown in Figure 5A. Hematoxylin and eosin–stained 
footpad sections demonstrated inflammation and infiltration of 
immune-competent cells (Figure 5B). In addition, similar results 
were obtained with an ear-swelling DTH model (data not shown). 
Analysis of footpad homogenates for cytokine expression in inflam-
mation by ELISA did not display differences in expression patterns 
of TNF-α, IL-1β, IL-6, and IFN-γ in WT and RAGE–/– mice (data not 
shown). As the RAGE gene has been deleted in RAGE–/– mice, these 
data suggest that at least in this model, the effect of sRAGE is not 
explained by blocking ligand engagement of the membrane-bound 
form of RAGE (i.e., full-length RAGE).
This result was surprising, given previous studies showing that 
application of sRAGE reduced DTH responses in WT mice. We 
therefore tested whether treatment of RAGE–/– mice with sRAGE 
would alter the inflammatory response in DTH. Indeed, applica-
tion of sRAGE significantly blocked the inflammatory response 
in DTH in both WT and RAGE–/– mice (Figure 5A; *P < 0.001). 
Reduced inflammation in the presence of sRAGE was confirmed 
histologically (Figure 5B). The efficacy of sRAGE treatment in 
RAGE–/– mice further provides support of the concept that the 
beneficial effects of sRAGE observed in DTH were not caused by 
prevention of ligand engagement of cell surface RAGE.
RAGE–/– mice are protected from lethal septic shock. After testing sev-
eral models for adaptive immune responses without detecting an 
obvious defect in RAGE–/– mice, we studied the effect of RAGE on 
the innate immune response. For this purpose, a model of poly-
microbial septic peritonitis, previously shown to be dependent on 
the innate immune response (49), was applied to RAGE–/– mice. 
Multibacterial peritonitis was induced by cecal ligation and punc-
ture (CLP) in WT and RAGE–/– mice, and the survival from the 
septic challenge was monitored for up to 7 days (Figure 6A). The 
efficacy of CLP was confirmed 24 hours after CLP in selected mice 
by monitoring of the partial pressure of arterial oxygen (PaO2) 
and the decrease in blood pressure and antithrombin III (AT III) 
serum levels as systemic markers of septicemia (Table 1). Up to 
80% of the RAGE–/– mice survived the septic shock, whereas WT 
mice were more susceptible to septic shock, as demonstrated by 
survival of 20% of the control group (P = 0.001; Figure 6A). Con-
sistent with that finding, RAGE–/– mice demonstrated a weaker 
decrease in blood pressure and AT III (Table 1). These differences 
were not due to the mixed background of RAGE–/– and WT mice, 
as CLP experiments were performed with a large number of mice 
and with RAGE–/– mice and WT littermates after five backcrosses 
to C57BL/6 mice (F5) with similar results (data not shown). Thus, 
the absence of RAGE apparently seems to protect mice from lethal 
multibacterial peritonitis.
Figure 5
RAGE–/– mice display normal inflammation in a model of DTH, 
and application of sRAGE blocks inflammation in DTH in WT and 
RAGE–/– mice. Age- and sex-matched WT and RAGE–/– mice were 
sensitized with mBSA. WT indicates C57BL/6 × 129/Sv mice. Control 
groups were challenged with ovalbumin (OVA), and DTH groups, 
with mBSA. Mouse groups receiving sRAGE were pretreated by 
intraperitoneal injection of solvent or sRAGE 24 and 12 hours prior 
to and 6 and 12 hours after local challenge with mBSA. The DTH 
experiment was repeated three times and the DTH with sRAGE treat-
ment was repeated two times with similar results (A). The mean clini-
cal inflammation score represents a summary of two independent 
experiments. Twenty-four hours after footpad injection, mice were 
subjected to clinical scoring (see Methods). Standard error is given 
(± SEM), and P < 0.05 was considered to be statistically significant 
(*). WT, gray bars; RAGE–/–, white bars. (B) Representative pictures 
of hematoxylin and eosin–stained footpad sections of experimental 
groups; magnification, ×400.
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Next, C57BL/6 mice were subjected to CLP and one experimental 
group received repeated sRAGE treatments to evaluate the effect of 
sRAGE in multibacterial peritonitis and septic shock (Figure 6B). 
Administration of sRAGE slightly improved survival of the treated 
mouse group (40% survival) compared with the group receiving 
solvent only (17% survival) (Figure 6B); however, in contrast to the 
RAGE deletion, this effect was not statistically significant (P = 0.42).
When CLP experiments were performed with WT and Tie2RAGE 
mice to investigate the effect of high initial RAGE expression in 
hematopoietic cells and the endothelium on the lethality of sep-
sis (Figure 6C), no difference in survival was seen after CLP in both 
mouse groups (50% survival, WT and Tie2RAGE). Thus, initial exces-
sive RAGE expression in hematopoietic and endothelial cells does not 
enhance the lethality of the CLP model.
To further define the role of RAGE in CLP-
dependent lethal septic shock, we crossed 
RAGE–/– mice with Tie2RAGE transgenic mice. 
WT, RAGE–/–, and Tie2RAGE × RAGE–/– were 
subjected to CLP and monitored for sur-
vival (Figure 7). Interestingly, RAGE–/– × 
Tie2RAGE were as susceptible as WT mice 
to lethality after CLP (40% survival), where-
as more than 80% of RAGE–/– littermates 
survived in the same experiment (Figure 7). 
These data indicate a pivotal role for RAGE 
expressed in hematopoietic and endothelial 
cells in mediating CLP-dependent death.
Notably, neither the number of inflammatory cells (Table 2) nor 
the cytokine levels (data not shown) differed significantly in WT and 
RAGE–/–mice that underwent CLP. In order to further address mech-
anisms by which loss of RAGE reduces lethality in septicemia, we col-
lected peritoneum, one of the target tissues of CLP, and studied the 
inflammatory response therein. Histological examination showed 
reduced numbers of inflammatory cells adherent to the peritoneum 
of RAGE–/– mice after CLP compared with that of WT mice (Figure 
8A; P = 0.001). While WT mice displayed an increase in cells adhering 
to the peritoneum after CLP (Figure 8A; WT “sham”) compared with 
CLP, P < 0.001), no increase in cell adhesion after CLP was observed 
in the peritoneum of RAGE–/– mice (Figure 8A; P = 0.059).
When EMSA for NF-κB–binding activity was performed with a 
protein extract derived from the peritoneum, only WT mice dem-
onstrated a strong increase in NF-κB–binding activity in response to 
CLP (Figure 8B). In contrast, there was no significant upregulation 
of NF-κB–binding activity in the peritoneum of RAGE–/– mice that 
underwent CLP. Similar results were obtained in lungs from mice 
that underwent CLP (Figure 8C). NF-κB activation was induced 
much more strongly in lungs of WT mice than in lungs of RAGE–/– 
mice (Figure 8C), indicating that the lack of excessive NF-κB activa-
tion in RAGE–/– mice might contribute to their reduced mortality.
Discussion
RAGE has been identified as a central signal transduction recep-
tor mediating long-lasting NF-κB activation in various cell types, 
Figure 6
RAGE–/– mice and WT mice treated with sRAGE are protected against 
septic shock induced by CLP. (A) Age- and sex-matched WT and 
RAGE–/– mice were subjected to CLP or sham operation and were mon-
itored for survival. WT indicates C57BL/6 × 129/Sv mice. A summary of 
four repeated experiments is shown. One to two sham-operated mice 
were included in each single experiment (data not shown) and did not 
show overt signs of disease. WT, filled squares; RAGE–/–, open circles. 
(B) Therapeutic effect of sRAGE treatment. CLP was performed in age- 
and sex-matched C57BL/6 mice. Mice received repeated intraperitoneal 
injections of sRAGE or solvent (LPS-free 0.9% NaCl) immediately after 
CLP (150 μg sRAGE/mouse) and 6, 12, 24, and 36 hours thereafter (70 
μg sRAGE/mouse). Two repeated experiments are summarized. WT 
treated with solvent, filled triangles; WT treated with sRAGE, asterisks. 
(C) Age- and sex-matched WT and Tie2RAGE mice were subjected to 
CLP and were monitored for survival. WT indicates transgene-negative 
littermates. A summary of two repeated experiments is shown. One 
to two sham-operated mice were included in each single experiment 
(data not shown) and did not show overt signs of disease. WT, filled 
squares; Tie2RAGE, open triangles.
Table 1
PaO2, median arterial blood pressure, and AT III plasma levels in WT and RAGE–/– (R) 
mice before and 24 hours after CLP
  WT R  P (WT vs. R P (WT vs. R 
 0 h 24 h 0 h 24 h  at 0 h) at 24 h)
PaO2 541.8 70.3 537.1 73.3 ± 28.4 n.d. n.d. 
MABP 114 ± 26.2 77 ± 19.5 111 ± 7.99 92 ± 20.3 0.815 0.085
AT III (%) 89.5 ± 3.5 64.1 ± 3.2  98 ± 5.7 76.3 ± 9.4 0.213 0.011A
AP < 0.05. 0 h, before CLP; 24 h, 24 hours after CLP; MAPB, median arterial blood pressure; n.d., 
not determined.
Downloaded on July 18, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/18704
research article
1646 The Journal of Clinical Investigation   http://www.jci.org   Volume 113   Number 11   June 2004
including mononuclear phagocytes and vascular endothelium (25). 
Its physiological role in inflammation was emphasized mainly by 
two key findings: (a) an increased expression of RAGE in inflam-
matory lesions of various diseases (20–24, 28) and (b) the capacity 
of the soluble receptor and anti-RAGE F(ab)2 fragments to block 
ongoing enterocolitis as well as the onset of DTH responses (37). 
Here we report the novel and surprising finding that RAGE–/– mice 
can mount normal adaptive immune responses. After mice were 
infected with P. pneumotropica, antibody subtypes and titers were 
comparable in the blood of RAGE–/– and of WT mice (our unpub-
lished observations). In addition, transfer of alloreactive T cells 
into irradiated RAGE–/– mice caused normal GvHD (our unpub-
lished observations). Finally, induction of EAE and DTH led to 
comparable onset and progression of the disease. These results 
indicate that sRAGE has effects other than simply blocking cell 
surface RAGE function. This view is further strengthened by our 
finding that application of sRAGE reduced DTH responses to the 
same extent in both RAGE–/– and WT mice.
This result was surprising, as RAGE ligands such as S100 pro-
teins are generated in DTH. Moreover, activation of NF-κB was 
comparable in WT and RAGE–/– mice after DTH and was reduced 
to the same extent in both mouse strains after treatment with 
sRAGE (our unpublished observations). One explanation is that 
indeed NF-κB activation and inflammation in DTH occur inde-
pendently of transmembrane RAGE. The inflammatory mediators 
scavenged by sRAGE additionally interact with cellular structures 
other than RAGE, as sRAGE blocks inflammation in RAGE–/– mice. 
It is also possible that compensatory mechanisms have evolved in 
RAGE–/– mice, leading to enhanced expression and/or function 
of other putative cell surface interaction sites for RAGE ligands. 
RAGE–/– mice, therefore, may provide a suitable model for outlin-
ing novel pathways linked to the inflammatory response.
However, blocking F(ab)2 fragments derived from anti-RAGE 
IgG reduces the inflammatory response in MOG or MBP-induced 
EAE (48). Furthermore, expression of dominant negative RAGE (a 
mutant form of RAGE lacking the cytosolic domain and capacity 
of signal transduction) selectively in CD4+ T cells also reduces the 
inflammatory reaction in EAE (48). Together with the observa-
tion that the outcome of EAE is worsened in Tie2RAGE mice with 
overexpression of RAGE in the vasculature, these data indicate that 
RAGE is involved in the perpetuation but not the initiation of EAE 
and thus might explain the differences among the different models. 
Differences between previous results and those shown here may be 
explained further by the different experimental conditions and/or 
by the induction of compensatory pathways in RAGE-deficient 
mice. However, the reduction of DTH by sRAGE in RAGE–/– mice 
“argues against” this explanation, unless deletion of RAGE caused 
upregulation of other cellular binding sites for RAGE ligands that 
emerge with a more prominent role in the complete absence of 
RAGE. The efficacy of sRAGE in the DTH response in RAGE–/– mice 
indicates that sRAGE is a tool for understanding ligands capable 
of binding to RAGE but also potentially to other binding sites. The 
possible relevance of other effector molecules’ mediating sRAGE 
binding opens the question of whether these putative binding sites 
share structurally significant homologies with the ligand-binding 
domain of RAGE. RAGE is capable of recognizing various ligands 
characterized by β-sheets and fibril formation (50). Taken togeth-
er with the data presented in the CLP model of septic shock, this 
puts RAGE in the group of PRRs important for innate immune 
responses (1–6, 44). Even though there is no doubt that blocking 
anti-RAGE F(ab)2 fragments target this receptor, it cannot present-
ly be excluded that they also recognize a tertiary structure similar to 
the PRR ligand-binding domain of RAGE. Studies looking at other 
molecules distinct from RAGE with a similar tertiary structure of 
their ligand-binding domain are currently underway.
Whereas initiation and perpetuation of inflammation was nor-
mal in RAGE–/– mice in models addressing predominantly the 
adaptive immune responses, a different result was obtained in 
CLP-mediated sepsis, a model largely dependent on the innate 
immune response. In contrast to WT mice, most RAGE–/– mice sur-
vived the septic shock. The contribution of RAGE to the outcome 
of survival was demonstrated by crossing of transgenic Tie2RAGE 
mice on the RAGE–/– genotype. The resulting animals were suscep-
tible to septic shock in the same way as WT mice. Ongoing stud-
ies indicate that hematopoietic and endothelial cells might be the 
most important sites of RAGE expression in CLP, as transplan-
tation of RAGE-expressing cells into RAGE–/– mice reduced sur-
vival (our unpublished observations). In this context, however, it 
is noteworthy that overexpression of RAGE did not enhance lethal-
ity in CLP (or modulated adaptive immune responses), indicating 
Figure 7
Rescue of RAGE expression in hematopoietic cells and the endothelium 
abolishes protection from septic shock independently of phagocytosis 
after CLP. Age- and sex-matched WT, RAGE–/–, and Tie2RAGE × 
RAGE–/– mice were subjected to CLP and were monitored for survival. 
Additionally, one to two sham-operated mice were included in each 
single experiment (data not shown). WT indicates C57BL/6 × 129/Sv 
mice. A summary of two repeated experiments is shown. WT, filled 
squares; RAGE–/–, open circles; Tie2RAGE × RAGE–/–, asterisks.
Table 2
Total blood counts of WT and RAGE–/– mice 24 hours after CLP
 WT R P value
Total leukocytes
 Control 5.0 cells/nl 8.1 cells/nl 0.172
 CLP 1.15 cells/nl 1.14/nl 0.974
Neutrophils
 Control 0.075 cells/nl 0.11 cells/nl 0.38
 CLP 0.022/nl 0.035 cells/nl 0.25
Lymphocytes
 Control 70% 62.5% 0.535
 CLP 37.5% 30% 0.179
Monocytes
 Control 21% 30% 0.43
 CLP 52% 56% 0.58
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that endogenous RAGE is sufficient to generate the full clinical 
course of septicemia. Likewise, treatment of Tie2RAGE mice with 
CML did not result in the expected “superinduction” of NF-κB but 
in a slightly weaker increase in NF-κB–binding activity than that in 
WT mice (Figure 3). These data and the observation that healthy 
RAGE–/– mice have a slightly proinflammatory phenotype, as indi-
cated by increased C-reactive protein (our unpublished observa-
tions), a slight increase in basal NF-κB–binding activity (Figure 8, 
B and C), and elevated cytokine levels suggest that RAGE might 
also be involved in the regulation of anti-inflammatory processes 
(our unpublished observations). The ability of tie2-driven RAGE 
overexpression to activate NF-κB in RAGE–/– mice upon engage-
ment of RAGE excludes the possibility that Tie2RAGE is simply 
serving as a “decoy receptor” or compensates for shedding of the 
receptor upon activation.
The data presented here implicate that RAGE-dependent acti-
vation of NF-κB plays a central role in modulating mortality 
after CLP. While WT, Tie2RAGE, and Tie2RAGE × RAGE–/– mice 
demonstrated strong NF-κB activation associated with high CLP-
mediated lethality, RAGE–/– mice were characterized by a reduced 
activation of NF-κB in septic shock target organs (lung, perito-
neum, and blood) and increased survival. Remarkably, recently 
described CD40–/– mice also demonstrate attenuated activation of 
NF-κB, delayed death, and improved survival after CLP (51), fur-
ther suggesting a causal relation between altered NF-κB regulation 
and mortality after polymicrobial sepsis.
The RAGE ligand HMGB1 has recently been identified as a 
late mediator of lethality in sepsis (45). Blocking HMGB by ethyl 
pyruvate, known to inhibit NF-κB activation in macrophages 
in vitro (52), prevented lethality in mice with established 
lethal sepsis and systemic activation (52). Thus, the lack of 
HMGB1-RAGE interactions in RAGE–/– mice is likely to con-
tribute to their improved survival after CLP. The observa-
tion that the competition for binding of ligand to RAGE by 
sRAGE was much less effective in reducing lethality than was 
RAGE deletion (Figure 6), however, indicates that additional 
mechanisms might be operative.
RAGE has recently been identified as counter-receptor of 
the β2-integrin Mac-1 able to mediate leukocyte adhesion 
(53). One mechanism by which excessive NF-κB activation 
might affect the outcome of disease is by amplifying expression 
of both RAGE and other adhesive receptors such as ICAM-1 and 
VCAM-1, thus promoting leukocyte recruitment. Consistent 
with this finding, the peritoneum of RAGE–/– mice undergoing 
CLP demonstrated significantly less adhesion of inflammatory 
cells (Figure 8A), while the total number of inflammatory cells 
was the same in total blood counts of WT and RAGE–/– mice 
(Table 2). CLP-challenged RAGE–/– mice presented with higher 
AT III levels. The difference observed was highly significant 24 
hours after CLP (WT vs. RAGE–/–, P = 0.011; Table 1). AT III is a 
marker of excessive activation of coagulation in septicemia. In 
addition, one might speculate that the moderate inflammation 
observed in RAGE–/– mice (our unpublished observations) acti-
vates cellular defense mechanisms that resist the polymicrobial 
challenge. Consistent with this hypothesis, CLP mice treated 
with anti-TNF-α have been reported to show a tendency toward 
a worsened outcome (54).
The studies in RAGE–/– mice presented here suggest that RAGE 
participates in inflammation in the CLP model of innate immu-
nity. The situation in the adaptive immune response may be more 
complex, however, as the presence of potent compensatory mecha-
nisms modulating cellular effector sites for RAGE ligands in that 
setting has not been ruled out. The data presented are not only 
useful for dissecting at which levels adaptive and innate immune 
responses may diverge, they also offer novel options for the devel-
opment of RAGE inhibitors for treating septicemia. The central 
role of RAGE in CLP and the demonstrated lack of an effect in 
adaptive immune responses using RAGE–/– mice, at least under 
Figure 8
Inflammatory cell adhesion on the peritoneum and NF-κB activa-
tion after CLP is reduced in RAGE–/– mice. Age- and sex-matched 
WT and RAGE–/– mice were sham-operated (Sham) or were sub-
jected to CLP. WT indicates C57BL/6 × 129/Sv mice. Twenty-four 
hours after sham operation or CLP, peritoneum was harvested for 
histology or isolation of nuclear proteins for EMSA. Experiments 
were repeated three times with similar results. (A) Representa-
tive pictures of hematoxylin and eosin–stained peritoneum sec-
tions from experimental groups showing adherent inflammatory 
cells; magnification, ×400. Cells in visual fields of serial sections 
of peritoneum were counted using a microscope, and the results 
were summarized and analyzed statistically. The standard error 
is given (± SEM), and P < 0.05 was considered to be statistically 
significant (*). WT, dark gray bars; RAGE–/–, light gray bars. (B) 
Representative EMSA for NF-κB–binding activity in peritoneum 
derived from WT and RAGE–/– mice 24 hours after sham opera-
tion or CLP. (C) Representative EMSA for NF-κB–binding activity 
in lungs derived from WT and RAGE–/– mice before (0 h) and 24 
hours after (24 h) CLP.
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these experimental conditions, present novel insights into distinct 
pathways involved in both types of immune responses.
Methods
Generation of RAGE–/– mice and Tie2RAGE mice
Generation of RAGE–/– mice. The RAGE targeting construct and the 
generation of RAGE–/– mice have been described in detail elsewhere 
(55, 56). Animals used in the described experiments were from F2 
or F5 backcrosses onto the C57BL/6 genetic background.
Generation of Tie2RAGE transgenic mice. The 2.1-kb promoter and 
10.5-kb first intron sequences from the murine Tie2 gene were 
cut from the vector pT2HlacZpA11.7 with HindIII and XbaI/NotI 
(kindly provided by T.N. Sato, Harvard Medical School, Boston, 
Massachusetts, USA) and were cloned into pBSK (Stratagene, 
Heidelberg, Germany). The resulting plasmids were called pTie2-
2.5 and pTie2-10.5, respectively (46). A 500-kb MboII-digested 
partial genomic RAGE fragment was cloned into the HindIII-
digested pTie2-2.5 plasmid. The 3.5-kb AvvII-digested part of the 
RAGE DNA was cloned into the resultant plasmid to complete 
the genomic RAGE sequence. The Tie2 enhancer was released from 
pTie2-10.5 by XmaI/ClaI and NotI digestion and was introduced 
into the RAGE-containing construct. Tie2RAGE mice were gen-
erated by pronuclear injection of the transgenic construct into 
fertilized eggs of C57BL/6 × DBA/2 F1 mice. Founder mice were 
tested by Southern blot analysis according to standard protocols. 
Heterozygous Tie2RAGE mice were used in all experiments.
RAGE–/– mice were mated to Tie2RAGE mice to reconstitute 
RAGE expression in hematopoietic and endothelial cells. The 
resulting Tie2RAGE × RAGE–/– mice were genotyped by Southern 
blot analysis. Mice were maintained in SPF housing conditions. 
Procedures in this study were approved by the Animal Care and 
Use Committee at the Regierungspräsidium Karlsruhe, Germany.
Analysis of RAGE expression in mutant mice
RT-PCR was used to evaluate RAGE expression at the mRNA 
level in RAGE–/– and Tie2RAGE mice. RNA from diverse tissues 
was prepared using an RNA isolation kit (RNAeasy, Qiagen, 
Hilden, Germany) and was transcribed into cDNA. Primers used 
were as follows: extracellular RAGE domain forward primer, 5′-
AACACAGGAAGAACTGAAGCTTGG-3′, and reverse primer, 
5′-CTTTGCCATCGGGAATCAGAAGTT-3′; and hypoxanthine 
guanine phosphoribosyl transferase (HPRT) forward primer, 5′-
GTTGGATCAAGGCCAGACTTTGTT-3′, and reverse primer, 5′-
GAGGGTAGGCTGGCCTATAGGCT-3′. The amplification cycles 
were as follows: for RAGE, one cycle of 95°C for 300 seconds, then 
28 cycles of 95°C for 60 seconds, 62°C 30 seconds, and 72°C 60 
seconds, followed by one cycle of 72°C for 600 seconds; for HPRT, 
one cycle of 94°C for 300 seconds, and 37 cycles of 94°C 30 sec-
onds, 60°C for 20 seconds, and 72°C for 40 seconds.
For evaluation of RAGE expression at the protein level, Western 
blot analysis and immunohistology was used. For Western blot 
analysis, proteins from “snap-frozen” mouse lungs were homog-
enized in 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1.5% NP-40, 10 
mM EDTA, 2 mM PMSF, and 0.5 mM DTT, and were extracted. 
SDS gel electrophoresis, blotting, and signal detection was per-
formed according to standard protocols (57) using the SuperSignal 
substrate (Pierce, Rockford, Illinois, USA). Polyclonal anti–human 
RAGE extracellular domain (1:3,000 dilution) was used as the pri-
mary antibody. This antibody was obtained by immunization of a 
rabbit with peptide derived from the extracellular RAGE domain 
(peptide sequence, CKGAPKKPPQRLEWKL). Rabbit serum was 
purified using protein G and was tested for specificity in Western 
blots in comparison with other antibodies against human RAGE. 
Similar signals were detected for different antibodies against RAGE. 
For signal detection, horseradish peroxidase–conjugated anti-rab-
bit (Amersham Bioscience, Freiburg, Germany) was utilized.
For immunohistology, mouse organs were fixed in 4% neutral 
buffered formaldehyde and paraffin-embedded, and 5-μm sections 
were cut. RAGE proteins were detected using goat anti–human 
RAGE at a dilution of 1:3,000 (kindly provided by Merck, Sharpe & 
Dohme, Essex, United Kingdom), and were visualized with a com-
mercial ABC-peroxidase technique (Vectorstain Elite Kit PK-6105; 
ALEXIS Deutschland GmbH, Grünberg, Germany) according to 
the manufacturer’s protocol.
Model of EAE
Two- to four-month-old mice were sensitized by subcutaneous 
injection of 200 μg MOG peptides 35–55; German Cancer Research 
Center, Heidelberg, Germany [ref. 58]) in incomplete Freund’s adju-
vant (Sigma-Aldrich, Deisenhofen, Germany) containing 2 mg/ml 
Mycobacterium tuberculosis (Difco BD Bioscience, Heidelberg, Ger-
many) and subsequent intraperitoneal injection of 200 ng pertussis 
toxin (Merck Calbiochem, Darmstadt, Germany) at the day of sen-
sitization and 48 hours later. Mice were monitored by experiment-
ers “blinded” to the identity of different mouse groups for clini-
cal signs 5–7 days per week for up to 60 days. The clinical grading 
system used was as follows: grade 0, normal mouse, no overt signs 
of disease; grade 1, limp tail or hind limb weakness but not both; 
grade 2, limp tail and hind limb weakness; grade 3, partial hind 
limb paralysis; grade 4, complete hind limb paralysis; and grade 5, 
death by EAE; sacrifice according to the animal protection law.
Model of DTH reaction
Two- to four-month-old mice were sensitized by subcutane-
ous injection over the left inguinal lymph node of 100 μl of an 
emulsion containing 25 mg/ml methylated BSA (mBSA; Sigma-
Aldrich), 0.9% NaCl, 50 mg/ml dextran (5 × 106 to 40 × 106 dalton 
molecular weight; Sigma-Aldrich), and 50% incomplete Freund’s 
adjuvant (Sigma-Aldrich). After 3 weeks, the left plantar hind 
paw was injected subcutaneously with 50 μl of 0.4 mg/ml mBSA 
in 0.9% NaCl. The control group received an injection with 50 μl 
of 0.4 mg/ml ovalbumin (control peptide). Where indicated, mice 
were pretreated by intraperitoneal injection of 100 μg sRAGE dis-
solved in LPS-free 0.9% NaCl at 24 and 12 hours prior to and 6 
and 12 hours after local challenge with mBSA (37). Control groups 
received solvent at the same time points. Twenty hours after food 
pad injection with mBSA, mice were assigned clinical scores by two 
investigators “blinded” to sample identity. The grading system for 
clinical assessment of DTH was as follows: 1, absence of inflamma-
tion; 2, slight rubor and edema; 3, moderate rubor and edema with 
skin wrinkles; 4, severe rubor and edema without skin wrinkles; 
and 5, severe rubor and edema with toe spreading. Afterward, mice 
were sacrificed and their feet were fixed in 4% formalin and decalci-
fied, and sections 5 μm in thickness were cut and were stained with 
hematoxylin and eosin according to standard protocols.
CLP
CLP was performed as described previously (49, 59, 60). In brief, 
mice 2–6 months old were anesthetized by intraperitoneal admin-
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istration of 75 mg/kg Ketanest (Parke-Davis, Berlin, Germany) 
and 16 mg/kg Rompun (Bayer AG, Leverkusen, Germany) in 0.2 
ml sterile pyrogen-free saline (Braun AG, Melsung, Germany). The 
cecum was exposed through a 1.0- to 1.5-cm abdominal midline 
incision and was subjected to a 50–80% ligation of the distal half 
followed by a single puncture with a 23-gauge needle. A small 
amount of stool was expelled from the puncture to ensure patency. 
The cecum was replaced into the peritoneal cavity and the abdomi-
nal incision was closed by layers with 5/0 Prolene thread (Ethicon, 
Norderstedt, Germany). No antibiotics were administered in this 
model. For sham-operated mice, which served as control in each 
experiment, the cecum was mobilized but no ligation and punc-
ture was performed. For experiments investigating the therapeu-
tic effect of sRAGE after CLP, the C57BL/6 mice used were pur-
chased from Wiga (Hannover, Germany). Where indicated, sRAGE 
was administered by intraperitoneal injection immediately after 
CLP (150 μg/mouse) and 6, 12, 24, and 36 hours thereafter (70 
μg/mouse). Control groups received the same volume (50–180 μl) 
of LPS-free 0.9% NaCl. CLP was performed by researchers “blind-
ed” to the identity of the treatment group. Survival after CLP was 
assessed four to six times a day for at least 7 days. Blood pressure 
was measured with femoral manometric catheters in anesthetized 
mice 24 hours after CLP.
For harvesting of tissues and organs for histopathology and 
NF-κB determination, mice were deeply anesthetized by 
intraperitoneal injection of 30 μl avertin per gram body weight 
(stock: 1 g tribromethanol and 620 μl 2-methyl-1-butanol; 180 μl of 
stock per 10 ml 0.9% NaCl) 24 hours after CLP. Tissues and organs 
were fixed in 4% formalin and sections 5 μm in thickness were cut 
and were stained with hematoxylin and eosin according to standard 
protocols. Kidney, lung, liver, heart, spleen, and peritoneum were 
subjected to histopathology. Infiltrated inflammatory cells in the 
peritoneum were counted using a microscope. Peritoneum, lungs, 
and total blood to be used for EMSA were harvested 24 hours after 
CLP and were immediately “snap-frozen” in liquid nitrogen.
EMSA
Nuclear proteins from “snap-frozen” mouse tissues were isolated 
as described in detail elsewhere (25). When NF-κB–binding activ-
ity was studied in total blood, blood collected from the retrobul-
bar region was dropped directly into the same volume of cold 
buffer A (10 mM HEPES-KOH, pH 7.9, at 4°C, 1.5 mM MgCl2, 
10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF, and 0.6% NP-40) and 
was mixed thoroughly. Blood was homogenized by being passed 
five times through a 20-gauge needle fitted to a syringe and by 
being centrifuged for 30 seconds at 700 g at 4°C to remove tissue 
debris. The supernatant was incubated on ice for 10 minutes and 
was centrifuged for 5 minutes at 11,000 g at 4°C. The supernatant 
was discarded and the nuclear pellet was resuspended in 100 μl 
of buffer B (25% glycerol, 20 mM HEPES-KOH, pH 7.9, at 4°C, 
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 
mM PMSF, 2 mM benzamidine, and 5 mg/ml leupeptin) and was 
incubated on ice for 20 minutes. Cellular debris were removed 
by 2 minutes of centrifugation at 4°C and the supernatant was 
“quick-frozen” at –80°C. Nuclear extracts were assayed for tran-
scription factor–binding activity using the NF-κB consensus 
sequence 5′-AGTTGAGGGGACTTTCCCAGGC-3′. Specificity of 
binding was ascertained by competition with a 160-fold molar 
excess of unlabeled consensus oligonucleotides and, where indi-
cated, by comparison with binding of recombinant NF-κB pre-
pared in erythrocyte lysate as described elsewhere (61). Protein-
DNA complexes were separated from unbound DNA probe by 
electrophoresis through 5% native polyacrylamide gels containing 
2.5% glycerol and 0.5× TBE. Gels were dried and exposed to x-ray 
film (Amersham Pharmacia, Freiburg, Germany) for 48–60 hours 
at –80°C with intensifying screens.
ELISA
Tissue homogenates, plasma, and peritoneal lavage fluid were 
subjected to ELISA for determination of IL-1β, IL-6, and TNF-α 
content. ELISA kits were purchased from R&D System GmbH 
(Wiesbaden-Nordenstadt, Germany).
Statistical analysis
Where indicated, values of experimental groups are given as 
mean, with bars showing the standard error of the mean (SEM). 
The means of groups were compared by analysis of variance 
using Student’s t test. A probability P < 0.05 was considered to be 
statistically significant.
Statistical analysis of time-dependent scores was performed by 
using generalized estimating equations. Covariates tested were 
group and experiment. The time dependency of repeated scores 
of individuals was modeled using a first-order autoregressive time 
series model. A local regression model was used to estimate the 
time-dependent mean score value. In addition, 95% confidence 
limits of the mean score were computed.
Figures 5, A–C, and 6 show the Kaplan-Meier estimates of group-
wise survival distributions. The log-rank test was used to compare 
two or more survival distributions. A result was denoted as statisti-
cally significant if the P value of its corresponding test statistic was 
5% or less. All statistical computations were performed using the 
statistical software package R, version 1.8 (62).
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